Stock Track | Cencora Soars 5.21% in pre-market as Fiscal Q3 Earnings Beat and Annual Profit Forecast Raised

Stock Track

Aug 05

Cencora Inc. shares soared 5.21% in pre-market trading on Wednesday, following the release of the company's fiscal third-quarter results that surpassed analyst expectations and an upward revision to its full-year profit guidance.

The pharmaceutical distributor reported adjusted earnings of $4.48 per diluted share for the quarter ended June 30, a 12% increase from $4.00 a year earlier and well above the consensus estimate of $4.35. Revenue rose 5.1% to $84.75 billion, slightly exceeding the $84.32 billion analysts had forecast. The strong performance was driven by growth in its U.S. Healthcare Solutions segment, particularly from specialty medicines and GLP-1 drugs.

Looking ahead, Cencora raised its fiscal 2026 adjusted earnings per share guidance to a range of $17.75 to $17.95, up from its prior outlook of $17.65 to $17.90. The company also maintained its revenue growth outlook of 4% to 6%. The positive earnings surprise and improved annual forecast fueled investor optimism, sending the stock sharply higher in the pre-market session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1112123418"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112123418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112123418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112123418","market":"sg","top_or_hot":-1,"title":"Stock Track | Cencora Soars 5.21% in pre-market as Fiscal Q3 Earnings Beat and Annual Profit Forecast Raised","media":"Stock Track","content":"<p>Cencora Inc. shares soared 5.21% in pre-market trading on Wednesday, following the release of the company's fiscal third-quarter results that surpassed analyst expectations and an upward revision to its full-year profit guidance.</p><p>The pharmaceutical distributor reported adjusted earnings of $4.48 per diluted share for the quarter ended June 30, a 12% increase from $4.00 a year earlier and well above the consensus estimate of $4.35. Revenue rose 5.1% to $84.75 billion, slightly exceeding the $84.32 billion analysts had forecast. The strong performance was driven by growth in its U.S. Healthcare Solutions segment, particularly from specialty medicines and GLP-1 drugs.</p><p>Looking ahead, Cencora raised its fiscal 2026 adjusted earnings per share guidance to a range of $17.75 to $17.95, up from its prior outlook of $17.65 to $17.90. The company also maintained its revenue growth outlook of 4% to 6%. The positive earnings surprise and improved annual forecast fueled investor optimism, sending the stock sharply higher in the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cencora Soars 5.21% in pre-market as Fiscal Q3 Earnings Beat and Annual Profit Forecast Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cencora Soars 5.21% in pre-market as Fiscal Q3 Earnings Beat and Annual Profit Forecast Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cencora Inc. shares soared 5.21% in pre-market trading on Wednesday, following the release of the company's fiscal third-quarter results that surpassed analyst expectations and an upward revision to its full-year profit guidance.</p><p>The pharmaceutical distributor reported adjusted earnings of $4.48 per diluted share for the quarter ended June 30, a 12% increase from $4.00 a year earlier and well above the consensus estimate of $4.35. Revenue rose 5.1% to $84.75 billion, slightly exceeding the $84.32 billion analysts had forecast. The strong performance was driven by growth in its U.S. Healthcare Solutions segment, particularly from specialty medicines and GLP-1 drugs.</p><p>Looking ahead, Cencora raised its fiscal 2026 adjusted earnings per share guidance to a range of $17.75 to $17.95, up from its prior outlook of $17.65 to $17.90. The company also maintained its revenue growth outlook of 4% to 6%. The positive earnings surprise and improved annual forecast fueled investor optimism, sending the stock sharply higher in the pre-market session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COR","symbol_name":"CENCORA","start_time":0,"source_url":"","article_id":"1112123418","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112123418","pubTimestamp":1785937156,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Cencora Inc. shares soared 5.21% in pre-market trading on Wednesday, following the release of the company's fiscal third-quarter results that surpassed analyst expectations and an upward revision to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COR":"CENCORA"},"translate_title":"股票跟踪 | 第三财季盈利超出预期并上调年度利润预测，Cencora 盘前飙升 5.21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COR":1},"content_text":"Cencora Inc. shares soared 5.21% in pre-market trading on Wednesday, following the release of the company's fiscal third-quarter results that surpassed analyst expectations and an upward revision to its full-year profit guidance.The pharmaceutical distributor reported adjusted earnings of $4.48 per diluted share for the quarter ended June 30, a 12% increase from $4.00 a year earlier and well above the consensus estimate of $4.35. Revenue rose 5.1% to $84.75 billion, slightly exceeding the $84.32 billion analysts had forecast. The strong performance was driven by growth in its U.S. Healthcare Solutions segment, particularly from specialty medicines and GLP-1 drugs.Looking ahead, Cencora raised its fiscal 2026 adjusted earnings per share guidance to a range of $17.75 to $17.95, up from its prior outlook of $17.65 to $17.90. The company also maintained its revenue growth outlook of 4% to 6%. The positive earnings surprise and improved annual forecast fueled investor optimism, sending the stock sharply higher in the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}